Clinical trial
Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer
NCT00071136 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 31, 2003
- Completion date
- August 31, 2006
- Enrollment
- 48
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.